Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9379856 | 0.83 | MAPK1 (0.40) | SIRT1MAPTKDM4ENSD2MAPK1 | |
| SCHEMBL21578840 | 0.82 | NR1H2 (0.43) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL1466407 | 0.82 | DDAH1 (0.43) | KDM4ELMNAPDE7AMEN1KMT2A | |
| SCHEMBL1466177 | 0.82 | PTGS1 (0.37) | MAPTKDM4EKDRALDH1A1PDE7A | |
| SCHEMBL26193556 | 0.78 | KDR (0.42) | MAPTKDRALDH1A1CYP2A6MEN1 | |
| SCHEMBL1465940 | 0.76 | FBP1 (0.42) | CYP2A6PDE7A | |
| SCHEMBL25798987 | 0.75 | STS (0.40) | — | |
| SCHEMBL5654163 | 0.73 | CA2 (0.44) | SIRT1MAPTKDM4ENSD2MAPK1 | |
| SCHEMBL15657924 | 0.71 | TUBB4A (0.36) | SIRT1MAPTKDM4ENSD2MAPK1 | |
| SCHEMBL9474580 | 0.70 | CYP2A6 (0.39) | MAPTTDP1ALDH1A1CYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| EP-0588785-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993003719-A1 | ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| US-5183818-A | Also for inhibiting leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0588785-A4 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1991-12-30 | — | — | EP | disclosed |
| WO-1990012008-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | SIRT1 1096/4885MAPT 3223/4885KDM4E 3629/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | SIRT1 1842/4885MAPT 4666/4885KDM4E 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.